Clinical Trials Browser

Phase 2/3 × Uterine Cervical Neoplasms × Clear all

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT07298642 2025-12-23

Extended-field Proton Therapy for Cervical Cancer

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Phase 2/3 Enrolling by invitation

Uterine Cervical Neoplasms

NCT01554397 2024-11-29

Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer

Phase 2/3 Completed

101 enrolled 13 charts

Carcinoma, Uterine Cervical Neoplasms

NCT06288373 2024-10-30

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT03668639 2021-12-14

Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Phase 2/3 Unknown

Uterine Cervical Neoplasms, Vomiting

NCT05149248 2021-12-08

CONDESA

Phase 2/3 Completed

Uterine Cervical Neoplasms, Neoplasms

NCT03163979 2017-05-23

PROGRAMMA

Phase 2/3 Unknown

Uterine Cervical Neoplasms